Biomemory Launches DNA Shield for Sovereign Data Protection

PARIS and BOSTON, Oct. 15, 2026 /CourierPR/ -- Biomemory, a leader in commercial DNA data storage and co-chair of the DNA Data Storage Alliance, today announced the launch of DNA Shield, its first commercial product for sovereign data protection. The announcement marks Biomemory's entry into sovereign data protection, a separate, offline layer held at rest, separated from the active control plane, and removed from the network-reachable attack surface, for the tailored set of information an organization cannot afford to lose, whatever new risks emerge around it.

The launch of DNA Shield follows two significant moves that reshaped Biomemory over the past year. In March 2026, the company acquired the assets of Catalog Technologies, the Boston-based pioneer of DNA data storage and computing, bringing together complementary technologies, intellectual property, and expertise. The acquisition gave Biomemory a second production and research hub in Boston alongside its Paris headquarters, and meaningfully expanded its intellectual property position.

In July 2026, Biomemory appointed Laurent Guengant as Chief Executive Officer. Guengant, a storage, telecom, and energy executive with more than 30 years of experience leading global businesses, strategy, and transformation, set the company on a path from research and innovation toward industrialization and commercial deployment.

Biomemory's new product, DNA Shield, is designed to protect what an organization cannot afford to lose or to have altered, such as cryptographic keys, proprietary industrial knowledge, regulated records, and institutional memory that must remain intact, secure, and verifiable over years or decades, independent of the systems built around them today. DNA Shield is designed so these assets stay recoverable and verifiable despite cyber attacks, organizational changes, infrastructure replacements, and regulatory scrutiny.

In practice, information first goes through secure onboarding, where the customer selects and encrypts the material in scope. DNA Shield then encodes it into synthetic DNA held offline under managed custody. Recovery follows a controlled process, deliberately triggered when needed, rather than routine or self-service access.

Initial use cases for DNA Shield include key custody continuity, helping organizations ensure that cryptographic key recovery schemes still work years after the people and vendors around them have changed, designed to complement a certified HSM rather than replace one. Another use case is Crown jewel industrial IP, an offline, sovereign copy of the small set of proprietary formulations, processes, or design parameters a company cannot afford to lose. Additionally, DNA Shield provides an independent, tamper-evident copy proving that critical records have not been altered since approval. Sovereign memory and golden records are also a longer-horizon lane for institutions preserving records that must outlast the systems and organizations that created them.

Biomemory is industrializing DNA as a new information tier: Molecular IT. Data is stored in synthetic DNA and, increasingly, searched and computed on. The company owns the full stack, from molecular biology to enterprise software, with industrial production in Paris and, following the Catalog's assets acquisition, in Boston. The company enters the market through sovereign data protection and trust preservation with DNA Shield, and expands along a dated roadmap into storage from 2029, with molecular search and compute beyond it.